Hypertension in Colombia: First pharmacogenomic risk profile stratified by ancestry
This study establishes Colombia's first ancestry-stratified pharmacogenomic risk profile for hypertension, revealing significant genetic differences across populations—particularly the poor correlation of San Basilio de Palenque with other cohorts and a critical lack of African representation—that underscore the need for diverse reference data to enable effective precision medicine.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
High blood pressure is a silent force that affects millions of people around the world, often without obvious symptoms until it causes serious harm. Doctors have many different medicines to lower it, but these drugs do not work the same way for everyone. One person might see their pressure drop perfectly with a specific pill, while another might get no benefit or suffer from unpleasant side effects. For decades, scientists have suspected that a person's unique genetic code plays a major role in this difference. This field of study, known as pharmacogenomics, looks at how our genes influence the way our bodies process medications. The goal is to move away from a "one-size-fits-all" approach and toward a more precise method where treatment is tailored to an individual's biology. However, most of the knowledge we have today comes from studying people with European ancestry. This leaves a huge gap in our understanding of how these drugs work in people with different genetic backgrounds, particularly in regions like Latin America where populations are a mix of Native American, European, and African heritage.
A team of researchers in Colombia has taken a significant step toward filling this gap by creating the first detailed map of how genetic ancestry affects the response to blood pressure medicines in their country. They focused on five distinct communities, each with a different genetic makeup, ranging from groups with a strong African heritage to those with a predominantly European background. By analyzing the genetic data of 1,254 individuals from these communities, the researchers looked for specific variations in DNA that are known to influence how the body handles common blood pressure drugs. They compared these local findings against the standard medical guidelines, which are largely based on studies of people from Europe and North America.
The results revealed a stark reality: the genetic profiles of these Colombian communities are not interchangeable. The researchers found that the people from San Basilio de Palenque, a community with a high percentage of African ancestry, had a genetic profile that was almost completely different from the communities with European ancestry. In fact, the genetic similarities between the African-descended group and the European-descended groups were so low that they were nearly non-existent. This means that a treatment plan based on the genetic data of a European patient could be scientifically inaccurate and potentially dangerous for a patient from San Basilio de Palenque. The study showed that certain genetic markers, which are rare in European populations, are very common in the African-descended group. These markers are linked to specific risks, such as a higher chance of developing diabetes or high cholesterol when taking certain common medications like hydrochlorothiazide or atenolol.
The researchers also examined the global scientific literature to understand where the current medical knowledge comes from. They found that the vast majority of studies on blood pressure genetics involve people of European descent, who make up more than three-quarters of the participants in these global research efforts. People of African descent, who make up a significant portion of the world's population, are represented by less than ten percent of the data. This imbalance means that the "rules" doctors currently use to prescribe medication are built on a very narrow slice of human diversity. The study highlights that applying these rules to mixed-race or African-descended populations is not just ineffective; it is a form of exclusion that ignores the unique biological realities of these groups.
Specific genes played a central role in these differences. The researchers identified that genes such as CYP2D6, KCNJ1, and TCF7L2 were the most influential in predicting how well a drug would work or how likely a patient was to experience side effects. For instance, a specific genetic variant found frequently in the San Basilio de Palenque community is associated with a higher risk of developing diabetes when taking hydrochlorothiazide. This same variant is much less common in the European-descended groups. Conversely, other variants that predict a reduced effectiveness of certain drugs were far more common in the European-descended populations. These differences are not minor statistical quirks; they represent fundamental biological differences that determine whether a medication will heal a patient or harm them.
The study concludes that precision medicine cannot be truly precise unless it includes the full spectrum of human genetic diversity. The researchers argue that the current reliance on data from European populations creates a system where marginalized groups are left behind, facing higher risks of treatment failure and toxicity. They emphasize that the genetic data from Colombia's diverse communities, which has been gathered through local initiatives, provides a crucial blueprint for a more equitable future. By recognizing that ancestry shapes the way drugs work, doctors can begin to move toward a system where treatment is guided by the specific genetic reality of the patient in front of them, rather than by a generalized model that fits only a fraction of the world's population. This work serves as a call to action for the global scientific community to diversify its research, ensuring that the benefits of modern medicine are shared by everyone, regardless of their genetic heritage.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.